The Leukemia Steering Committee (LKSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in adult leukemia. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The LKSC's membership comprises NCTN group representatives, NCI-funded consortia representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.
Co-Chairs
Jessica Altman, M.D.
Northwestern University
Laura Michaelis, M.D.
Medical College of Wisconsin
Members
Ramzi Abboud, M.D.
Washington University in Saint Louis
Omar Abdel-Wahab, M.D.
Memorial Sloan Kettering Cancer Center
Sarit Assouline, M.D.
Jewish General Hospital
Harry Erba, M.D., Ph.D.
Duke University
Boris Freidlin, Ph.D.
National Cancer Institute
Joseph Jurcic, M.D.
Columbia University
Margaret Kasner, M.D.
Thomas Jefferson University
Neil Kay, M.D.
Mayo Clinic
Brian Koffman, MDCM
Patient Advocate
Lisa Y. Law, M.D.
Kaiser Permanente
Richard Little, M.D.
National Cancer Institute
Selina M. Luger, M.D.
University of Pennsylvania
Ryotaro Nakamura, M.D.
City of Hope
Megan Othus, Ph.D.
Fred Hutchinson Cancer Research Center
John Plastaras, M.D., Ph.D.
University of Pennsylvania
Crystal Reinhart, Ph.D.
University of Illinois
Mikkael Sekeres, M.D., M.S.
University of Miami, Sylvester Cancer Center
Lois Shepherd, M.D.
Queen's University
B. Douglas Smith, M.D.
Johns Hopkins
Malcolm Smith, M.D., Ph.D.
National Cancer Institute
Wendy Stock, M.D.
University of Chicago
Richard Stone, M.D.
Dana-Farber Cancer Institute
Zhuoxin Sun, Ph.D.
Harvard University
Geoffrey L. Uy, M.D.
Washington University School of Medicine
Eunice Wang, M.D.
Roswell Park Cancer Institute
NCI CCCT Program Director
Elena Schwartz, Ph.D., M.S.
elena.schwartz@nih.gov